CD70 and acute myeloid leukemia: CD70, a type 2 transmembrane glycoprotein from the tumour necrosis factor (TNF) family, is a compromising target for CAR‐T cell therapy in AML because it is present on both leukaemic blasts and leukaemia stem cells in AML patients.